Contraceptive applications of progesterone receptor modulators

References

• Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod 1996; 11(Suppl. 2)20–23
   PubMedGoogle Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz I M. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2005; 11: 293–307
   PubMed Web of Science ®Google Scholar
• Ortiz M E, Ortiz R E, Fuentes M A. Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey Cebus apella. Hum Reprod 2004; 19: 1352–1356
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Williams R F, Hodgen G D. Inhibition of ovulation by progestin analogs (agonists vs antagonists): Preliminary evidence for different sites and mechanisms of actions. Contraception 1996; 53: 55–64
   PubMed Web of Science ®Google Scholar
• Banaszak S, Brudney A, Donnelly K. Modulation of the action of chorionic gonadotropin in the baboon (Papio anubis) uterus by a progesterone receptor antagonist (ZK 137. 316). Biol Reprod 2000; 63: 820–825
   PubMed Web of Science ®Google Scholar
• Petersen A, Bentin-Ley U, Ravn V. The antiprogesterone Org 31710 inhibits human blastocyst-endometrial interactions in vitro. Fertil Steril 2005; 83(Suppl. 1)1255–1263
   PubMedGoogle Scholar
• Lalitkumar P GL, Lalitkumar S, Meng C X. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod 2007; 22: 3031–3037
   PubMed Web of Science ®Google Scholar
• Glasier A, Thong K J, Dewar M. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992; 327: 1041–1044
   PubMed Web of Science ®Google Scholar
• Webb A M, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ 1992; 305: 927–931
   PubMed Web of Science ®Google Scholar
• Ashok P W, Stalder C, Wagaarachchi P T. A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG 2002; 109: 553–560
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Piaggio G, Ding J. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: A WHO multicentre randomised trial. Lancet 2002; 360: 1803–1810
   PubMed Web of Science ®Google Scholar
• Ashok P W, Wagaarachchi P T, Flett G M, Templeton A. Mifepristone as a late post-coital contraceptive. Hum Reprod 2001; 16: 72–75
   PubMed Web of Science ®Google Scholar
• World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: A randomised trial. Lancet 1999; 353: 697–702
   PubMed Web of Science ®Google Scholar
• Xiao B L, von Hertzen H, Zhao H, Piaggio G. A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum Reprod 2002; 17: 3084–3089
   PubMed Web of Science ®Google Scholar
• Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998; 57: 363–369
   PubMed Web of Science ®Google Scholar
• Wilcox A J, Weinberg C R, Baird D D. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333: 1517–1521
   PubMed Web of Science ®Google Scholar
• Psychoyos A, Nikas G, Saranits L, Gravanis A. Hormone anti-implantation agents: antiprogestins. Hum Reprod 1995; 10(Suppl. 1)140–150
   PubMedGoogle Scholar
• Creinin M D, Schlaff W, Archer D F. Progesterone receptor modulator for emergency contraception: A randomized controlled trial. Obstet Gynecol 2006; 108: 1089–1097
   PubMed Web of Science ®Google Scholar
• Philibert D, Deraedt R, Teutsch G. RU 38486: A potent antiglucocorticoid in vivo. The VII International Congress of Pharmacology. TokyoJapan 1981
   Google Scholar
• Baird D T, Brown A, Cheng L. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids 2003; 68: 1099–1105
   PubMed Web of Science ®Google Scholar
• Baird D T, Brown A, Critchley H O. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18: 61–68
   PubMed Web of Science ®Google Scholar
• Brown A, Cheng L, Lin S, Baird D T. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002; 87: 63–70
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho P C, Van der Spuy Z M. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007; 22: 2428–2436
   PubMed Web of Science ®Google Scholar
• Cameron S T, Glasier A F, Logan J. Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. Br J Obstet Gynaecol 1996; 103: 1222–1229
   PubMedGoogle Scholar
• Batista M C, Cartledge T P, Zellmer A W. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: A potential new contraceptive strategy. Am J Obstet Gynecol 1992; 167: 60–65
   PubMed Web of Science ®Google Scholar
• Liu J H, Garzo G, Morris S. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab 1987; 65: 1135–1140
   PubMed Web of Science ®Google Scholar
• Steinauer J, Pritts E A, Jackson R, Jacoby A F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004; 103: 1331–1336
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Gemzell K Danielsson, Marions L, Swahn M L. Contraceptive use of antiprogestin. Eur J Contracept Reprod Health Care 1999; 4: 103–107
   PubMedGoogle Scholar
• Marions L, Gemzell Danielsson K, Swahn M L, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998; 70: 813–816
   PubMed Web of Science ®Google Scholar
• Marions L, Viski S, Gemzell-Danielsson K. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod 1999; 14: 2788–2790
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92: 3582–3589
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Elger W, Stickler T. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005; 20: 1090–1099
   PubMed Web of Science ®Google Scholar
• Croxatto H B, Salvatierra A M, Croxatto H D, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993; 8: 201–207
   PubMed Web of Science ®Google Scholar
• Cameron S T, Critchley H O, Thong K J. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996; 11: 2518–2526
   PubMed Web of Science ®Google Scholar
• Pei K, Xiao B, Jing X. Weekly contraception with mifepristone. Contraception 2007; 75: 40–44
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Mandl I, Marions L. Mechanisms of action of mifepristone when used for emergency contraception. Contraception 2003; 68: 471–476
   PubMed Web of Science ®Google Scholar
• Plourd D M, Rayburn W F. New contraceptive methods. J Reprod Med 2003; 48: 665–671
   PubMed Web of Science ®Google Scholar
• Glasier A F, Smith K B, van der Spuy Z M. Amenorrhea associated with contraception – An international study on acceptability. Contraception 2003; 67: 1–8
   PubMed Web of Science ®Google Scholar
• Bergeron C, Nogales F F, Masseroli M. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23: 1102–1108
   PubMed Web of Science ®Google Scholar
• Horne F M, Blithe D L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007; 13: 567–580
   PubMed Web of Science ®Google Scholar
• Mutter G L, Bergeron C, Deligdisch L. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21: 591–598
   PubMed Web of Science ®Google Scholar
• Spitz I M, Van Look P F, Coelingh Bennink H J. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids 2000; 65: 817–823
   PubMed Web of Science ®Google Scholar
• Gemzell K Danielsson, van Heusden A M, Killick S R. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002; 17: 2588–2593
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhu H, Wang A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000; 15: 1969–1972
   PubMed Web of Science ®Google Scholar
• Critchley H OD, Kelly R W, Brenner R M, Baird D T. The endocrinology of menstruation – a role for the immune system. Clin Endocrinol (Oxf) 2001; 55: 701–710
   PubMed Web of Science ®Google Scholar
• The ESHRE Capri Workshop Group. Endometrial bleeding. Hum Reprod 2007; 13: 421–431
   Web of Science ®Google Scholar
• Archer D F. Endometrial bleeding during hormone therapy: The effect of progestogens. Maturitas 2007; 57: 71–76
   PubMed Web of Science ®Google Scholar
• Jain J K, Nicosia A F, Nucatola D L. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003; 68: 1115–1119
   PubMed Web of Science ®Google Scholar
• Jain J K, Li A, Yang W. Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril 2007; 87: 8–23
   PubMed Web of Science ®Google Scholar
• Jain J K, Li A, Yang W. Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. Hum Reprod 2006; 21: 798–809
   PubMed Web of Science ®Google Scholar
• Li A, Felix J C, Yang W. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception 2007; 76: 57–65
   PubMed Web of Science ®Google Scholar
• Nayak N R, Slayden O D, Mah K. Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. Contraception 2007; 75: S104–S111
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Vani S, Carpen O. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: A pilot study. Hum Reprod 2007; 22: 2515–2522
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Delivery options for contraception. Drug Discov Today 2005; 10: 977–985
   PubMed Web of Science ®Google Scholar